Introduction
Angiogenesis, the formation of new blood vessels from existing ones, is an essential process if solid tumours are to grow beyond 2-3 mm 3 , since diffusion is no longer sufficient to supply the tissue with oxygen and nutrients [1] . Tumour-induced angiogenesis is a complex multistep process that follows a characteristic cascade of events mediated and controlled by growth factors, cellular receptors and adhesion molecules [2] [3] [4] . Activated endothelial cells express the integrin α v β 3 receptor, whereas this integrin receptor is absent on quiescent endothelial cells. In addition, α v β 3 is expressed on the cell membrane of various tumour cell types such as ovarian cancer, neuroblastoma, breast cancer and melanoma. α v β 3 Integrin expressed on endothelial cells modulates cell migration and survival during angiogenesis, whereas α v β 3 integrin expressed on carcinoma cells potentiates metastasis by facilitating invasion and movement across blood vessels. Due to this restricted expression of α v β 3 in tumours, α v β 3 is considered a suitable candidate for tumour targeting [5] . Radiolabelled ligands for this integrin could be used as tracers to noninvasively visualise α v β 3 expression in tumours. Noninvasive visualisation of α v β 3 expression might provide information about the angiogenic process and the responsiveness of a tumour to antiangiogenic drugs. Furthermore, noninvasive determination of α v β 3 expression potentially can be used to monitor the effect of antiangiogenic drugs in patients.
The α v β 3 integrin is a transmembrane protein consisting of two noncovalently bound subunits, α and β. This integrin can bind to the arginine-glycine-aspartic acid (RGD) amino acid sequence present in extracellular matrix proteins such as vitronectin, fibrinogen and laminin [6] . Based on the RGD tripeptide sequence a series of small peptides have been designed to antagonise the function of the α v β 3 integrin [7] . Especially the cyclic peptide derivatives have a relatively high affinity for the α v β 3 integrin. Radiolabelled cyclic RGD peptides have the potential for early detection of rapidly growing tumours and noninvasive visualisation of tumour metastasis and therapeutic response in cancer patients.
Over the last several years, significant progress has been made in the development of α v β 3 -targeting radiotracers for the visualisation of α v β 3 expression in tumours by single photon emission computed tomography (SPECT) and positron emission tomography (PET).
Haubner and coworkers developed the first α v β 3 -specific PET tracer [
18 F]Galacto-RGD [8] , a glycosylated cyclic pentapeptide, which demonstrated that PET with [ 18 F]Galacto-RGD enables receptor-specific monitoring of α v β 3 expression in murine tumour models. It was the first PET tracer applied in patients with cancer which could successfully image α v β 3 expression with good tumour to background ratios [9] . In addition, a strong correlation between tracer uptake and α v β 3 expression was observed [10] . In the mean time, another RGD-based PET tracer, [ 18 F]AH111585, has been developed and evaluated in breast cancer patients [11] . [ 18 F]AH111585 was demonstrated to be safe and metabolically stable and could visualise tumours in breast cancer patients. Although both 18 F-labelled RGD monomers bind specifically to the α v β 3 integrin, their clinical translation is partly hampered by the time-consuming multistep 18 F-labelling procedure and the necessity of a cyclotron facility to produce this PET isotope.
An interesting alternative is the use of the generatorproduced radionuclide 68 Ga. The application of 68 Galabelled peptides has attracted considerable interest for cancer imaging, because of its physical characteristics [12] . 68 111 In]DOTA-RGD [13] . They found that especially in the blood and also in tumour the uptake of the 68 Ga-labelled peptide was higher than the 111 In-labelled counterpart which could be explained by different complex stabilities for the Ga-DOTA and the In-DOTA complexes, resulting in transmetallation of gallium to transferrin. The group in Stanford conjugated RGD monomers and multimers to p-SCN-Bn-NOTA and labelled them with 68 Ga for imaging integrin expression in a U87MG glioblastoma xenograft model [14, 15] . They clearly observed by increasing RGD units an increase in α v β 3 affinity and tumour uptake. In addition, it was possible to increase the α v β 3 receptor-binding affinity of the RGD dimer by coupling the two RGD peptide units via Gly 3 and PEG 4 linkers.
Here, we radiolabelled mono-, di-and tetrameric RGD peptides with 68 Ga and studied the tumour targeting potential of these peptides in vitro and in vivo. This is the first study in which mono-, di-and tetrameric RGD peptides labelled with 68 Ga, for PET imaging of α v β 3 expression, are directly compared with their 111 In-labelled counterparts.
Materials and methods

Synthesis of DOTA-conjugated RGD peptides
The mono-, di-and tetrameric RGD peptides were synthesised using Fmoc-based solid-phase peptide synthesis (SPPS) as described previously [16] [17] [18] [19] . The structural formulas of DOTA-E-c(RGDfK), DOTA-E-[c(RGDfK)] 2 and DOTA-E{E[c(RGDfK)] 2 } 2 are shown in Fig. 1 
Analysis
The radiochemical purity was determined by reversed-phase high-performance liquid chromatography (RP-HPLC) on an Agilent 1100 system (Agilent Technologies, Palo Alto, CA, USA) using a C18 column (RX-C18, 4.6×250 mm, Zorbax) eluted with a gradient mobile phase [0-5 min 97% buffer A, 5-15 min 97% buffer A to 0% buffer A, buffer A=0.1% trifluoroacetic acid (TFA) in H 2 O, buffer B=0.1% TFA in acetonitrile] at 1 ml/min. The radioactivity of the eluate was monitored using an in-line NaI radiodetector (Raytest GmbH, Straubenhardt, Germany). Elution profiles were analysed using Gina Star software (version 2.18, Raytest GmbH, Straubenhardt, Germany). An additional quality control after purification on an HLB cartridge was performed by instant thin-layer chromatography (ITLC) using TECControl™ chromatography strips (Biodex Medical Systems, Shirley, NY, USA). The strips were developed using two different mobile phases. Mobile phase I was 0.1 M CH 3 COONH 4 /0.1 M EDTA (1:1 v/v) and mobile phase II was 0.25 M CH 3 COONH 4 /MeOH (1:1 v/v). The strips were analysed using a Fujifilm BAS-1800II Scanner (Fuji Photo Film Co., Tokyo, Japan).
Octanol/water partition coefficient
To an Eppendorf tube filled with 0.5 ml of the radiolabelled peptide in PBS, pH 7.4, 0.5 ml octanol was added. After the tube was vigorously vortexed for 2 min at room temperature, the two layers were separated by centrifugation (100 g, 5 min). Then, 100-μl samples were taken from each layer and radioactivity was measured in a well-type gamma counter (Wallac Wizard 3", PerkinElmer, Waltham, MA, USA) and Log P values were calculated (n=3).
In vitro stability
The stability of the 111 In-and 68 Ga-labelled RGD peptides was determined by incubating the compounds in both PBS and human serum for 2 h at 37°C. Before analysis of the serum samples the serum proteins were precipitated by adding an equal volume of MeCN to the samples. Subsequently, serum samples were centrifuged for 5 min at 13,500 g. The PBS samples were analysed without any sample preparation. An aliquot of the serum and the PBS sample were injected onto HPLC.
Protein binding
To determine their serum protein-binding properties, the 68 Ga-and 111 In-labelled peptides were incubated in fresh human serum at 37°C. After 2 h, the samples were analysed with fast protein liquid chromatography (FPLC), using a BioSep-Sec-S 3000 column (300×4.60 mm, Phenomenex, Utrecht, The Netherlands) with an isocratic mobile phase (PBS, 1 ml/min). Biodistribution studies
In the right flank of 6-to 8-week-old female nude BALB/c mice, 0.2 ml of a cell suspension of 2×10 6 cells/ml SK-RC-52 cells was injected subcutaneously (s.c.). Two weeks after inoculation of the tumour cells, mice were injected intravenously (i.v.) with the 111 In-or 68 Ga-labelled RGD peptides (0.2-0.89 nmol) in 0.2 ml PBS+0.5% BSA. Mice were killed by CO 2 asphyxiation 2 h post-injection (p.i.) (five mice/group). Blood, tumour and the major organs and tissues were collected, weighed and counted in a gamma counter. The percentage injected dose per gram (%ID/g) was determined for each sample.
The receptor-mediated localisation of the radiolabelled RGD peptides was investigated by determining the biodistribution of the 111 In-or 68 Ga-labelled compounds in the presence of an excess (100-fold excess) unlabelled DOTA-E-[c(RGDfK)] 2 (n=3). DOTA-E-[c(RGDfK)] 2 was used for these "blocking studies" as in our previous studies this compound was demonstrated to be α v β 3 specific [20, 21] . All animal experiments were approved by the local Animal Welfare Committee in accordance with the Dutch legislation and carried out in accordance with their guidelines.
MicroPET imaging
Mice with s.c. SK-RC-52 tumours were injected i.v. with 10 MBq 68 Ga-labelled mono-, di-or tetrameric RGD peptide per mouse (0.89 nmol). Two hours after the injection of the peptide, mice were scanned on an animal PET/CT scanner (Inveon®, Siemens Preclinical Solutions, Knoxville, TN, USA) with an intrinsic spatial resolution of 1.5 mm [22] . The animals were placed in a supine position in the scanner. PET emission scans were acquired over 15 min. CT images were acquired for anatomical correlation directly after PET imaging (spatial resolution 113 μm, 80 kV, 500 μA, exposure time 300 ms).
Scans were reconstructed using Inveon Acquisition Workplace software version 1.2 (Siemens Preclinical Solutions, Knoxville, TN, USA), using an ordered subset expectation maximisation 3-D/maximum a posteriori (OSEM3D/MAP) algorithm with the following parameters: matrix 256×256×159, pixel size 0.43×0.43×0.8 mm 3 and a beta value of 0.1.
Statistical analysis
All mean values are given ± standard deviation (SD). Statistical analysis was performed using the one-way analysis of variance. Bonferroni corrections for multiple comparisons were applied. The level of significance was set at p<0.05. In-labelled RGD mono-, di-and tetramer were −4.38± 0.25, −3.95±0.05 and −4.15±0.07, respectively.
Results
Radiolabelling
In vitro stability
Determination of the stability of the 111 In-and 68 Galabelled RGD peptides indicated high stability of the compounds. There was no evidence of release of 68 Ga or 111 In from the peptides or radiolysis of any of the compounds in both PBS and human serum (data not shown). After 2 h incubation at 37°C more than 95% of the activity was still associated with the DOTA-conjugated cyclic peptides and no significant reduction was observed. . At 2 h p.i., the tumour uptake was significantly higher for the 68 Ga-labelled tetramer (7.11±0.67%ID/g), compared to that of the dimer (5.24±0.27%ID/g) and that of the monomer (3.30±0.30%ID/g). For the 111 In-labelled analogues, there was no difference in tumour uptake between the tetramer (7.32±2.45%ID/g) and dimer (5.61± 0.85%ID/g), whereas the tumour uptake of the 111 Inlabelled dimer was significantly higher than that of the 111 In-labelled monomer (2.70±0.29%ID/g).
Coinjection of an excess unlabelled DOTA-E-[c (RGDfK)] 2 (50 μg) along with 0.5 μg of In-labelled tetramer could not be blocked. Kidney uptake was remarkably high for the 68 
Galabelled tetramer compared to its 111
In-labelled analogue. Fused PET and CT scans are shown in Fig. 4 . PET scans were in line with the biodistribution data. On all PET scans, the tumour could be clearly visualised. The 68 Ga-labelled tetramer showed the highest tumour uptake compared to the monomer and dimer. All three tracers showed some uptake in the kidneys, especially the tetramer. On the other hand, the monomer demonstrated relatively high intestinal uptake. The 68 Ga-labelled tetramer showed the highest tumour to background ratio and therefore this tracer is the most suitable for imaging α v β 3 expression by PET.
Discussion
In this study, the feasibility of using 68 Ga-labelled multimeric RGD peptides for radionuclide imaging of the α v β 3 integrin expression with PET was investigated. The radiolabelled mono-, di and tetrameric RGD peptides were very hydrophilic as demonstrated by their partition coefficients (Log P octanol/water ). The Log P values varied between −4.38±0.25 for the 111 In-labelled monomer and −3.76±0.07 for the 68 Ga- In it is assumed that the four nitrogen atoms of the DOTA macrocycle and the four oxygen atoms of the carboxylic groups are involved in the complexation. Several research groups have applied the multivalent concept to prepare cyclic RGD peptides with an enhanced binding affinity and demonstrated that the multimeric RGD peptides have an enhanced localisation in α v β 3 -expressing tumours [17, 19, [25] [26] [27] [28] [29] [30] . Although the advantages of multimeric RGD peptides as targeting molecules are universally accepted, the cause of the enhanced affinity of the multimeric RGD analogues for integrin α v β 3 is still a matter of debate [31] . Cells can form a cluster of many monovalent receptors on the cell surface [32] , and particularly multimeric ligands with a spacer between the binding moieties could span the required distance between binding sites and could then bind multiple receptors simultaneously. On the other hand, multimeric compounds could have enhanced affinity due to statistical rebinding: the receptor binding of one RGD unit will significantly enhance the local concentration of the second RGD unit in the vicinity of the receptor. This could lead to an enhanced α v β 3 -binding rate or a reduced α v β 3 -dissociation rate of the RGD multimer [19] . The distance between the RGD units of the multimers used in this study is relatively short and therefore statistical rebinding might be the most likely explanation for the increased affinity in the series tetramer > dimer > monomer.
The three 68 Ga-labelled RGD peptides showed a remarkable difference in kidney uptake. The uptake of the 68 Ga-labelled tetrameric RGD peptide was at 2 h p.i. significantly higher than that of the 68 Ga-labelled dimer and monomeric RGD peptides. In the integrin specificity experiment, the excess of nonradiolabelled RGD peptide partly inhibited the kidney uptake of the radiolabelled monomer and dimer, but not the kidney uptake of the radiolabelled tetramer. This indicates that different mechanisms cause the relatively high uptake of the RGD peptides in the kidneys. Wu and coworkers have recently shown by immunohistochemistry that the endothelial cells of the glomeruli vessels in the kidneys express β 3 integrins [33] , which could explain the partly specific kidney uptake of the RGD peptide. Furthermore, the difference in charge between the three peptides could cause the difference in tubular reabsorption. A trend has been observed that positively charged peptides are more efficiently reabsorbed by the proximal renal tubular cell than neutral peptides [34] . Due to the presence of more guanidine groups, the tetrameric RGD peptide is more positively charged than the dimeric and monomeric RGD peptides. Remarkably, the 68 Ga-labelled tetramer demonstrated a much higher kidney uptake than the 111 In-labelled tetramer which may hamper its clinical application.
Other nontumour tissues such as lung, liver and colon also showed specific uptake of the mono-, di-and tetrameric RGD peptides, suggesting α v β 3 expression in these tissues. Indeed, β 3 expression in these tissues has been described for rodents as well as for humans [33, 35] 68 Ga]DOTA-RGD had the highest tracer uptake in all organs [13] . Especially, the radioactivity concentration in the blood was significantly higher for [ 68 Ga]DOTA-RGD compared with [
111 In]DOTA-RGD. The authors hypothesised that the lower complex stability of the 68 Ga-DOTA complex could result in transchelation of gallium to transferrin. In our study, the 68 Ga-labelled peptides, especially the dimer and tetramer, did not show enhanced blood levels as compared to the 111 In-labelled counterparts. In addition, in our in vitro studies no evidence of instability of the 68 Ga-DOTA complex or proteinbinding activity was observed. This is in line with the recent observation of Haukkala and coworkers who found that there was no evidence of dissociation of 68 Ga from DOTA in the blood [36] . Although DOTA has a larger cavity than NOTA and the log stability constants are in favour of the Ga-NOTA complex compared with the Ga-DOTA complex [37, 38] , the 68 Ga-DOTA complex is stable enough for in vitro and in vivo studies.
In conclusion, the tetrameric RGD peptide demonstrated improved tumour targeting compared to the dimeric RGD peptide. Analogously, the dimeric RGD peptide exhibits improved tumour targeting compared to the monomeric RGD peptide. The results of the biodistribution study of the 68 
Gaand 111
In-labelled dimer and tetramer are rather comparable. The 68 Ga-labelled tetrameric RGD peptide is a suitable ligand for the noninvasive visualisation of α v β 3 expression in vivo.
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